Domenico Angiletta

Prof. Domenico Angiletta

University of Bari Aldo Moro, Bari, Puglia, Italy
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
RPRaffaele Pulli
Raffaele Pulli
WDWalter Dorigo
Walter Dorigo
AFAaron Fargion
Aaron Fargion
GPGiovanni Pratesi
Giovanni Pratesi
AIAlessandro Alessi Innocenti
Alessandro Alessi Innocenti
CPCarlo Pratesi
Carlo Pratesi

1 January 2012 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
RPRaffaele Pulli
Raffaele Pulli
WDWalter Dorigo
Walter Dorigo
GPGiovanni Pratesi
Giovanni Pratesi
AFAaron Fargion
Aaron Fargion
DADomenico Angiletta
Domenico Angiletta
CPCarlo Pratesi
Carlo Pratesi

1 April 2014 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
DADomenico Angiletta
Domenico Angiletta
RPRaffaele Pulli
Raffaele Pulli
DMDavide Marinazzo
Davide Marinazzo
PFPietro Frotino
Pietro Frotino
LMLuisa Maiellaro
Luisa Maiellaro
GRGuido Regina
Guido Regina

20 January 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
PMPaolo Maggi
Paolo Maggi
CBChiara Bellacosa
Chiara Bellacosa
VCValentina Carito
Valentina Carito
FPFrancesco Perilli
Francesco Perilli
ALAntonio Lillo
Antonio Lillo
GAGioacchino Angarano
Gioacchino Angarano
The aim of this study was to evaluate the cardiovascular risk among patients treated for more than 5 years with regimens based on nevirapine or efavirenz. A total of 276 patients were retrospectively evaluated, 156 of whom were treated with nevirapine and 120 with efavirenz, by examining traditional risk factors and detecting the presence of subclinical carotid lesions with colour-Doppler ultrasonography. When comparing the data at baseline and follow-up in the nevirapine group, total cholesterol, low-density lipoprotein cholesterol (LDLc) and triglycerides showed a significant decrease, while high-density lipoprotein cholesterol increased. Ultrasound data, obtained in a subgroup of 67 patients, did not show significant changes for those treated with nevirapine. In the efavirenz group, total cholesterol, LDLc, triglycerides, glycaemia, body mass index and the number of patients with a pathological ultrasound significantly increased. When comparing the two groups at baseline and follow-up, nevirapine patients had significantly higher values of total cholesterol, LDLc and triglycerides at baseline, while total cholesterol and LDLc differed non-significantly at follow-up; triglycerides became significantly lower in the nevirapine arm with respect to the efavirenz group. Glycaemia was comparable between the two groups at baseline, while it was significantly lower in the nevirapine group at follow-up. The number of pathological ultrasound findings was significantly higher in the efavirenz group at follow-up. Patients treated with nevirapine demonstrated a better lipid and glucose profile and a lower tendency to develop subclinical atherosclerotic lesions.

1 April 2015 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
RPRaffaele Pulli
Raffaele Pulli
WDWalter Dorigo
Walter Dorigo
AFAaron Fargion
Aaron Fargion
DADomenico Angiletta
Domenico Angiletta
LALeonidas Azas
Leonidas Azas
CPCarlo Pratesi
Carlo Pratesi

16 April 2014 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
AAArtor Niccoli Asabella
Artor Niccoli Asabella
MCMarco Ciccone
Marco Ciccone
FCFrancesca Cortese
Francesca Cortese
Pietro ScicchitanoPietro Scicchitano
Pietro Scicchitano
MGMichele Gesualdo
Michele Gesualdo
GRGiuseppe Rubini
Giuseppe Rubini